
中文名称:盐酸安非他酮
CAS号:31677-93-7
分子式: C13H18ClNO.HCl 分子量: 276.20
产品形式: Hydrochloride
研发状态: Recruiting
研发用途: Obesity Morbid; Bariatric Surgery Candidate; Medication Persistence
研究机构: Zuyderland Medisch Centrum; Nederlandse Obesitas Kliniek
研发日期: March 21 2023
研发阶段: Phase 4
Amfebutamone (Bupropion) HCl(Wellbutrin) is a selective norepinephrine-dopamine reuptake inhibitor with IC50 of 6.5 and 3.4 μM for the reuptake of dopamine and norepinephrine, respectively.
中文名称: 帕利伐米
CAS号:31645-39-3
分子式: C4H11Cl2N2O2P 分子量: 221.02
产品形式: Free Base
研发状态: Unknown status
研发用途: Advanced Solid Tumors
研究机构: Alaunos Therapeutics
研发日期: Jun-11
研发阶段: Phase 1
Palifosfamide (ZIO-201, Isophosphamide mustard) is a novel DNA alkylator and the active metabolite of ifosfamide with potential antineoplastic activity.
中文名称:2-(2-呋喃基)-7-[3-(4-甲氧基苯基)丙基]-7H-吡唑并[4,3-e][1,2,4]噻唑并[1,5-c]嘧啶-5-胺
CAS号:316173-57-6
分子式: C20H19N7O2 分子量: 389.41
产品形式: Free Base
研发状态: Completed
研发用途: Healthy
研究机构: Biogen
研发日期: Sep-07
研发阶段: Phase 1
SCH-442416 is a selective antagonist of adenosine A2A receptor that binds to human and rat adenosine A2A receptors with Ki of 0.048 nM and 0.5 nM, respectively.
中文名称:别嘌醇
CAS号:315-30-0
分子式: C5H4N4O 分子量: 136.11
产品形式: Free Base
研发状态: Recruiting
研发用途: Gout
研究机构: InventisBio Co. Ltd
研发日期: April 17 2023
研发阶段: Phase 2
Allopurinol is a purine analog inhibitor of the enzyme xanthine oxidase, used to treat gout or kidney stones, and to decrease levels of uric acid.
中文名称:4-(苯基甲基)-1-哌嗪乙酸 2-[[2-羟基-3-(2-烯丙-1-基)苯基]亚甲基]酰肼
CAS号:315183-21-2
分子式: C23H28N4O2 分子量: 392.49
产品形式: free base
研发状态: Recruiting
研发用途: Platelet Aggregation Spontaneous; Vascular Thrombosis
研究机构: University of California Davis
研发日期: July 20 2023
研发阶段: Not Applicable
PAC-1 is a potent procaspase-3 activator with EC50 of 0.22 μM and the first small molecule known to directly activate procaspase-3 to caspase-3.
中文名称:瑞加德松
CAS号:313348-27-5
分子式: C15H18N8O5 分子量: 390.35
产品形式: free base
研发状态: Recruiting
研发用途: Myocardial Ischemia; Coronary Artery Disease
研究机构: GE Healthcare; Covance
研发日期: May 20 2021
研发阶段: Phase 1 : Phase 2
Regadenoson (CVT-3146, Lexiscan) is a selective A2A adenosine receptor agonist with coronary vasodilating activity.
即日起可免费注册成为会员, 建立企业产品库, 免费上传产品目录, 企业介绍等. 让你的产品直接呈现给客户.
试运营阶段,所有广告业务5折优惠
